Europe
MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Research & Development, LLC, has initiated a phase 3 clinical trial of guselkumab in pediatric patients suffering from chronic plaque psoriasis.
A study aimed at demonstrating the clinical superiority of THN201 over a standard of care treatment for this severely debilitating symptom
Liver4Life is a project of Wyss Zurich, a joint research and development center of the ETH Zurich and the University of Zurich in the fields of Regenerative Medicine and Robotics.
Fermentalg and ADL BioPharma today announced the signing of a long-term manufacturing contract to produce Fermentalg’s algal oil DHA ORIGINS®.
Sareum Holdings plc announces that it has made the formal selection of a development candidate from its TYK2 inhibitor programme to advance through preclinical development as a potential new targeted therapy for certain cancers.
New investment will allow indication expansion of Minoryx’s lead compound, MIN-102
Allergy Therapeutics plc today announces preliminary results for the year ended 30 June 2018.
Fusion Antibodies plc announces that it has been informed by Alan Mawson, a Non-Executive Director of the Company, that on 24 September 2018 he purchased 8,500 ordinary shares in the Company (“Ordinary Shares”) at a price of 67 pence per Ordinary Share via his personal pension scheme.
Earlier this month, Novo Nordisk announced it was laying off 400 staffers in Denmark and China. Today, Reuters reports that the Danish company plans to lay off about 250 people in the United States.
An estimated 15 million people in the United States have allergies to more than 170 different foods, according to the non-profit Food Allergy Research and Education. New health data suggests the frequency of food allergies in children under 18 has risen 70 percent since 1997, CNBC reported.
PRESS RELEASES